Skip to main content
SK Bioscience Co.,Ltd logo

SK Bioscience Co.,Ltd — Investor Relations & Filings

Ticker · 302440 ISIN · KR7302440003 KO Manufacturing
Open in API
Filings indexed 386 across all filing types
Latest filing 2026-05-29 Governance Information
Country KR South Korea
Listing KO 302440

About SK Bioscience Co.,Ltd

https://www.skbioscience.com/

SK Bioscience is a biopharmaceutical company focused on the research, development, manufacturing, and commercialization of vaccines and biological products. Spun off from SK Chemicals in 2018, the company develops its own pipeline of vaccines, including cell-culture-based influenza vaccines and a COVID-19 vaccine, utilizing its established R&D and production platforms. In addition to its proprietary products, SK Bioscience provides global Contract Development and Manufacturing Organization (CDMO) services, offering end-to-end support from process development to large-scale commercial manufacturing for international partners. The company is dedicated to promoting public health by providing innovative preventative solutions to address global health challenges.

Recent filings

Filing Released Lang Actions
기업지배구조보고서공시
Governance Information Classification · 95% confidence The document is a detailed corporate governance report (“기업지배구조보고서”) containing the company’s governance policies, board composition, committee charters, compliance tables, and narrative on governance practices. It is not merely an announcement or summary; it is the full governance report itself. This aligns precisely with the Governance Information category (CGR).
2026-05-29 Korean
대규모기업집단현황공시[연1회공시및1/4분기용(개별회사)]
Governance Information Classification · 70% confidence The document is a detailed statutory disclosure of the company’s conglomerate (기업집단) status and corporate governance: - It contains extensive information on the group structure, individual company financials, board and committee compositions, shareholder structures, and related‐party transactions. - It is not an earnings release, proxy, or interim/annual report; nor is it merely an announcement of a filing. It is the actual governance and group‐status report. - This aligns with the Governance Information (CGR) category, which covers detailed reports on internal rules, board structure, and governance practices.
2026-05-29 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 90% confidence The document is titled “분기보고서 (제 9 기)” covering the period 2026.01.01 to 2026.03.31, contains detailed interim financial statements, business overview, segment sales, production statistics, and risk management. This matches a comprehensive quarter (interim) report with actual financial data, not merely an announcement or summary. Therefore, it is classified as an Interim/Quarterly Report. Q1 2026
2026-05-13 Korean
기업설명회(IR)개최(안내공시)
Investor Presentation Classification · 95% confidence The document is a short announcement (700 characters) about an upcoming investor presentation (IR) event scheduled for May 7, 2026, including details such as date, location, participants, and purpose (to explain Q1 2026 results and business status). It does not contain actual financial statements or detailed financial analysis but rather serves as a notice for the event. According to the classification rules, such announcements about investor presentations are classified as Investor Presentation (IP). The document is not the presentation itself but an announcement of it, yet given the specific category for investor presentations and the nature of the content, IP is the best fit. Confidence is high due to clear keywords like '기업설명회(IR)' and detailed event info.
2026-05-06 Korean
연결재무제표기준영업(잠정)실적(공정공시)
Earnings Release Classification · 95% confidence The document is titled as a preliminary (잠정) consolidated financial performance announcement for the period 2026-01-01 to 2026-03-31, which corresponds to a quarterly period. It contains summarized financial data such as sales, operating profit, and net income for the current quarter, previous quarter, and year-over-year comparisons. The document explicitly states that the figures are provisional and subject to change after external audit review. The length of the document is 2271 characters, which is relatively short and typical for an earnings release rather than a full interim report. There is no detailed financial statement or comprehensive analysis, only key highlights and summary figures. Therefore, this document fits the definition of an Earnings Release (ER), which is an initial announcement of quarterly financial results with key highlights only. Q1 2026
2026-05-06 Korean
주요사항보고서(자기주식취득결정)
Transaction in Own Shares Classification · 95% confidence The document is a Korean ‘주요사항보고서’ (material event report) titled “자기주식 취득 결정” (Decision to acquire treasury shares) filed with the Financial Services Commission/KRX. It details the number of shares, amounts, acquisition period, methods, and relevant statutory calculations for a share repurchase. This matches “Transaction in Own Shares” (POS).
2026-04-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.